# Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

> **NCT06441019** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 42 (estimated)

## Conditions studied

- Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab

## Interventions

- **DRUG:** HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab

## Key facts

- **NCT ID:** NCT06441019
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441019, "Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06441019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*